We would like to use third party cookies for our own marketing purposes. We do not monetise your data otherwise.
Industries
About Us
Our Work
Blog
21 Oct 2025
Where AI monitoring on aseptic and fill-finish lines cuts contamination risk, shortens time-to-detect, and produces Annex 1-grade evidence.
3 Oct 2025
Which AI use cases in pharma R&D and manufacturing are deployable now, where they deliver measurable ROI, and how to sequence them against GxP.
2 Oct 2025
Sterile manufacturing failures cost more than a write-off. AI can help prevent them when its role is evidenced to Annex 1, FDA and Annex 22 expectations.
1 Oct 2025
Biologics R&D ships faster when AI is treated as a decision-latency layer, not a discovery moonshot. Where the loop actually shortens.
30 Sep 2025
How AI vision systems support Annex 1 cleanroom compliance — and where they sit on the GxP boundary that determines validation scope.
29 Sep 2025
A practical guide for pharma teams to assess, test, and control nitrosamine risks across synthesis, formulation, packaging, and lifecycle monitoring.
26 Sep 2025
How ICH Q2(R2) and Q14 reshape analytical method development, validation, and lifecycle control for pharma labs and regulatory submissions.
25 Sep 2025
How DSCSA and EU FMD barcodes work in practice: 2D Data Matrix, serialisation, scan workflows, and the data hygiene that keeps verification reliable.
24 Sep 2025
GxP in pharma decides whether an AI tool needs validation by what its output touches; the AI Act adds a separate, case-by-case risk test.
23 Sep 2025
How to detect, correct and validate batch effects in Cell Painting assay profiles, and which correction method fits your scenario.
22 Sep 2025
Artificial intelligence in pathology needs an artefact and focus gate, explanation tests beyond attention maps, and release gates that report uncertainty.
19 Sep 2025
How GAMP 5 validation applies to AI/ML: why Categories 3-5 strain, Appendix D11's lifecycle evidence, retraining control and the AI maturity model.
17 Sep 2025
Automated visual inspection in pharma QC: defect sensitivity, GMP validation, cost vs manual, AI vs deterministic CV, and the difficult-product envelope.
Edge imaging for cell and gene therapy: continuous in-process monitoring, Annex 1-aligned contamination control, and GMP-grade validation.
16 Sep 2025
Biotech and AI for climate: bioprocess optimisation, carbon capture, sustainable manufacturing. The proven use cases vs the still-experimental.
15 Sep 2025
Vision analytics in cell and gene therapy 2026: CV inspection for autologous workflows, GMP validation, defect classes covered, where humans still win.
How AI helps clinical genetics teams triage variants of uncertain significance, score de novo changes, and connect sequencing output to patient care.
11 Sep 2025
How CV-based automated visual inspection holds defect sensitivity for sterile injectables under GMP — validation, integration, and the limits of AI.
9 Sep 2025
Real-life computer vision examples by industry, and how computer vision and NLP combine in VQA, CLIP retrieval and production document AI pipelines.
8 Sep 2025
Observable CV pipelines for CCTV: modular boundaries, metrics that make video analytics debuggable, upstream camera failure detection, and SLOs.
5 Sep 2025
Real-time AI risk prediction in pharma trials only survives GxP validation if the POC is instrumented for it from week one. Five concrete requirements.
EU GMP Annex 11 for computerised systems 2026: scope, AI/ML validation, vs 21 CFR Part 11, retraining controls, 2025 revision impact.
4 Sep 2025
Outdated video surveillance costs more than hardware: exploited firmware, lost footage, weak evidence and cameras that block video remote monitoring.
2 Sep 2025
How GDPR reshapes AI-driven CCTV: lawful basis, DPIA scope, transparency duties, breach reporting, and the human-review boundary for automated decisions.
1 Sep 2025
AI vision models for pharma QC: CNNs, ViTs, and hybrids by defect class. Where each wins, validation under GMP, and the QC stack integration.
29 Aug 2025
AI for telecommunications pays back on fraud detection, fault detection and predictive maintenance, sits on top of OSS/BSS, and needs streaming data to…
28 Aug 2025
What is visual inspection, and how do you prove an automated vision system equals or beats manual inspection under GMP, using rates and confidence…
27 Aug 2025
False alarms in AI video surveillance 2026: causes, architectural fixes, measurement that drives change, feedback loops, remote-monitoring economics.
Where AI sits inside GxP for pharma manufacturing and trials: what falls in scope, what stays out, and how validation work scales with risk.
26 Aug 2025
GxP compliance for AI in pharma 2026: GxP vs non-GxP boundary, AI/ML validation rules, drift management, GAMP AI guidance integration with QA roles.
25 Aug 2025
How AI supports clinical genetics interpretation, where computer vision fits, and what FDA-cleared medical-device CV demands of the pipeline.
19 Aug 2025
Computer vision improves safety only when detection pipelines include a verification stage. Without it, false alarms collapse operator trust.
14 Aug 2025
Augmented reality in telecommunication: customer-care and field AR use cases, the end-to-end latency budget, uplink needs, and why pilots stutter on live…
13 Aug 2025
How the FDA regulates an AI medical device: SaMD scope, 510(k), De Novo and PMA, PCCPs, validation evidence gaps and what a 2026 warning letter shows.
12 Aug 2025
3D cell models explained: how spheroids, organoids and organ-on-chip differ from 2D culture, and where ML imaging analysis helps and where it fails.
11 Aug 2025
A four-quadrant portfolio view of computer vision in telecom: infrastructure inspection, retail CX, NOC video quality, and customer-premises edge CV.
8 Aug 2025
How telecom supply chain software with AI cuts delays, manages multi-tier suppliers, and links sourcing to field operations end-to-end.
6 Aug 2025
Inside-out tracking and motion in XR: sensor stack, in-vs-out trade-offs, hand tracking without controllers, on-device CV, latency vs classical SLAM.
5 Aug 2025
How AI-driven problem-solving reshapes decision-making: real-time analysis, risk stratification, and integration with legacy systems.
1 Aug 2025
How AI, deep learning, and LLMs reshape Wall Street trading, risk, compliance, and back-office operations — with the engineering constraints that matter.
31 Jul 2025
The main augmented reality challenges in UX: physical context and safety, device comfort limits, information overload, privacy, and pilots that stall at…
How AI is reshaping communication across meetings, support, and global teams — and where the feasibility line sits for current models.
29 Jul 2025
How AI-augmented operations research actually pays back in retail and adjacent operations: forecasts feed solvers, OR keeps the decision-making rigorous.
28 Jul 2025
The GenAI Divide: State of AI in Business 2025 behind the 95% GenAI pilot figure: what it measured, where it is misread, and what to settle before budget.
25 Jul 2025
Lightweight vision models compared: what counts as small, which compact detector or small VLM fits the task, and why to re-measure on your data and…
24 Jul 2025
Image recognition in 2026: what it actually is, which algorithms still earn their keep, where the pipeline fails, and how it sits next to facial…
23 Jul 2025
How AI reshapes cloud computing: smarter infrastructure, stronger cloud security, and the operational discipline needed to keep both in balance.
22 Jul 2025
XR motion tracking architecture in 2026: sensor stacks, inside-out vs outside-in, hand tracking, SLAM, and the latency budget AI tracking changes.